Peroxisome Proliferator-Activated Receptor β/δ (PPAR β/δ) as a Potential Therapeutic Target for Dyslipidemia

Dyslipidemia is a powerful predictor of cardiovascular disease in patients at high risk (Turner et al., 1998), such as type 2 diabetic patients. Lowering of LDL-C is the prime target for treatment (2002), but even with intensification of statin therapy, a substantial residual cardiovascular risk rem...

Descripción completa

Detalles Bibliográficos
Autores: Barroso Fernández, Emma, Serrano-Marco, Lucía, Salvadó Serra, Laia, Palomer Tarridas, Francesc Xavier, Vázquez Carrera, Manuel
Tipo de recurso: capítulo de libro
Estado:Versión publicada
Fecha de publicación:2012
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/174830
Acceso en línea:https://hdl.handle.net/2445/174830
Access Level:acceso abierto
Palabra clave:Trastorns del metabolisme dels lípids
Peroxisomes
Lipid metabolism disorders
id ES_c79ecdccc8ff4fe245583f9ddf4a6340
oai_identifier_str oai:diposit.ub.edu:2445/174830
network_acronym_str ES
network_name_str España
repository_id_str
spelling Peroxisome Proliferator-Activated Receptor β/δ (PPAR β/δ) as a Potential Therapeutic Target for DyslipidemiaBarroso Fernández, EmmaSerrano-Marco, LucíaSalvadó Serra, LaiaPalomer Tarridas, Francesc XavierVázquez Carrera, ManuelTrastorns del metabolisme dels lípidsPeroxisomesLipid metabolism disordersPeroxisomesDyslipidemia is a powerful predictor of cardiovascular disease in patients at high risk (Turner et al., 1998), such as type 2 diabetic patients. Lowering of LDL-C is the prime target for treatment (2002), but even with intensification of statin therapy, a substantial residual cardiovascular risk remains (Barter et al., 2007; Miller et al., 2008; Fruchart et al., 2008; Shepherd et al., 2006). This may partly be due to atherogenic dyslipidemia. This term is commonly used to describe a condition of abnormally elevated plasma triglycerides and low high-density lipoprotein cholesterol (HDL-C), irrespective of the levels of LDL-C (Grundy, 1995). In addition to these key components, increased levels of small, dense LDL-C particles are also present, which in conjunction with the former components conform the also called “lipid triad” (Shepherd et al., 2005). Other abnormalities include accumulation in plasma of triglyceride-rich lipoproteins (TLRs), including chylomicron and very-low-density lipoprotein (VLDL) remnants. This is reflected by elevated plasma concentrations of non- HDL-C and apolipoprotein B-100 (apoB). Postprandially, there is also accumulation in plasma of TLRs and their remnants, as well as qualitative alterations in LDL and HDL particles. Thus, hypertriglyceridemia is associated with a wide spectrum of atherogenic lipoproteins not measured routinely (Taskinen, 2003). The presence of this lipid plasma profile with high triglyceride and low HDL-C levels have been shown to increase the risk of cardiovascular events independent of conventional risk factors (Bansal et al., 2007; Barter et al., 2007; deGoma et al., 2008). In fact, guidelines recommend modifying high triglyceride and low HDL-C as secondary therapeutic targets to provide additional vascular protection (2002). The presence of atherogenic dyslipidemia is seen in almost all patients with triglycerides > 2.2 mmol/l and HDL-C < 1.0 mmol/l, virtually all of whom have type 2 diabetes or abdominal obesity and insulin resistance (Taskinen, 2003)...IntechOpen2012info:eu-repo/semantics/bookPartinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/174830Llibres / Capítols de llibre (Farmacologia, Toxicologia i Química Terapèutica)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReprodució del document publicat a: http://doi.org/10.5772/27647Chapter 11 in: Kelishadi, Roya. 20xx. Dyslipidemia: From Prevention to Treatment. IntechOpen. ISBN: 978-953-307-904-2. DOI: 10.5772/1182. pp. 215-234.http://doi.org/10.5772/27647cc by (c) Barroso Fernández, Emma et al., 2012http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1748302026-05-27T06:46:51Z
dc.title.none.fl_str_mv Peroxisome Proliferator-Activated Receptor β/δ (PPAR β/δ) as a Potential Therapeutic Target for Dyslipidemia
title Peroxisome Proliferator-Activated Receptor β/δ (PPAR β/δ) as a Potential Therapeutic Target for Dyslipidemia
spellingShingle Peroxisome Proliferator-Activated Receptor β/δ (PPAR β/δ) as a Potential Therapeutic Target for Dyslipidemia
Barroso Fernández, Emma
Trastorns del metabolisme dels lípids
Peroxisomes
Lipid metabolism disorders
Peroxisomes
title_short Peroxisome Proliferator-Activated Receptor β/δ (PPAR β/δ) as a Potential Therapeutic Target for Dyslipidemia
title_full Peroxisome Proliferator-Activated Receptor β/δ (PPAR β/δ) as a Potential Therapeutic Target for Dyslipidemia
title_fullStr Peroxisome Proliferator-Activated Receptor β/δ (PPAR β/δ) as a Potential Therapeutic Target for Dyslipidemia
title_full_unstemmed Peroxisome Proliferator-Activated Receptor β/δ (PPAR β/δ) as a Potential Therapeutic Target for Dyslipidemia
title_sort Peroxisome Proliferator-Activated Receptor β/δ (PPAR β/δ) as a Potential Therapeutic Target for Dyslipidemia
dc.creator.none.fl_str_mv Barroso Fernández, Emma
Serrano-Marco, Lucía
Salvadó Serra, Laia
Palomer Tarridas, Francesc Xavier
Vázquez Carrera, Manuel
author Barroso Fernández, Emma
author_facet Barroso Fernández, Emma
Serrano-Marco, Lucía
Salvadó Serra, Laia
Palomer Tarridas, Francesc Xavier
Vázquez Carrera, Manuel
author_role author
author2 Serrano-Marco, Lucía
Salvadó Serra, Laia
Palomer Tarridas, Francesc Xavier
Vázquez Carrera, Manuel
author2_role author
author
author
author
dc.subject.none.fl_str_mv Trastorns del metabolisme dels lípids
Peroxisomes
Lipid metabolism disorders
Peroxisomes
topic Trastorns del metabolisme dels lípids
Peroxisomes
Lipid metabolism disorders
Peroxisomes
description Dyslipidemia is a powerful predictor of cardiovascular disease in patients at high risk (Turner et al., 1998), such as type 2 diabetic patients. Lowering of LDL-C is the prime target for treatment (2002), but even with intensification of statin therapy, a substantial residual cardiovascular risk remains (Barter et al., 2007; Miller et al., 2008; Fruchart et al., 2008; Shepherd et al., 2006). This may partly be due to atherogenic dyslipidemia. This term is commonly used to describe a condition of abnormally elevated plasma triglycerides and low high-density lipoprotein cholesterol (HDL-C), irrespective of the levels of LDL-C (Grundy, 1995). In addition to these key components, increased levels of small, dense LDL-C particles are also present, which in conjunction with the former components conform the also called “lipid triad” (Shepherd et al., 2005). Other abnormalities include accumulation in plasma of triglyceride-rich lipoproteins (TLRs), including chylomicron and very-low-density lipoprotein (VLDL) remnants. This is reflected by elevated plasma concentrations of non- HDL-C and apolipoprotein B-100 (apoB). Postprandially, there is also accumulation in plasma of TLRs and their remnants, as well as qualitative alterations in LDL and HDL particles. Thus, hypertriglyceridemia is associated with a wide spectrum of atherogenic lipoproteins not measured routinely (Taskinen, 2003). The presence of this lipid plasma profile with high triglyceride and low HDL-C levels have been shown to increase the risk of cardiovascular events independent of conventional risk factors (Bansal et al., 2007; Barter et al., 2007; deGoma et al., 2008). In fact, guidelines recommend modifying high triglyceride and low HDL-C as secondary therapeutic targets to provide additional vascular protection (2002). The presence of atherogenic dyslipidemia is seen in almost all patients with triglycerides > 2.2 mmol/l and HDL-C < 1.0 mmol/l, virtually all of whom have type 2 diabetes or abdominal obesity and insulin resistance (Taskinen, 2003)...
publishDate 2012
dc.date.none.fl_str_mv 2012
dc.type.none.fl_str_mv info:eu-repo/semantics/bookPart
info:eu-repo/semantics/publishedVersion
format bookPart
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/174830
url https://hdl.handle.net/2445/174830
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reprodució del document publicat a: http://doi.org/10.5772/27647
Chapter 11 in: Kelishadi, Roya. 20xx. Dyslipidemia: From Prevention to Treatment. IntechOpen. ISBN: 978-953-307-904-2. DOI: 10.5772/1182. pp. 215-234.
http://doi.org/10.5772/27647
dc.rights.none.fl_str_mv cc by (c) Barroso Fernández, Emma et al., 2012
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Barroso Fernández, Emma et al., 2012
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv IntechOpen
publisher.none.fl_str_mv IntechOpen
dc.source.none.fl_str_mv Llibres / Capítols de llibre (Farmacologia, Toxicologia i Química Terapèutica)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419194431307776
score 15.301629

Similares en LA Referencia